This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on December 11, 1997, 8 a.m. to 6 p.m., and December 12, 1997, 8 a.m. to 3:30 p.m.

Location: DoubleTree Hotel, Plazas I, II, and III, 1750 Rockville Pike, Rockville, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research, 1401 Rockville Pike, Rockville, MD 20852, 301-827-3514, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting.

Agenda: On December 11, 1997, the committee will discuss and provide recommendations on the issue of FDA’s donor deferral policy regarding men who have had sex with another man ever one time since 1977.

On the morning of December 12, 1997, the meeting will sit as a medical device panel and make recommendations on the issue of in vitro diagnostic detection of human immunodeficiency virus (HIV) viral load, sponsor, Roche Molecular Systems. In the afternoon, the Committee will hear an informational presentation on hepatitis C virus (HCV) risk in sexual partners of positive individuals.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 1, 1997. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person by January 7, 1998, and submit a brief statement of the nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


Michael A. Friedman, Deputy Commissioner for Operations.

[FR Doc. 97–30705 Filed 11–20–97; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Subcommittee of the Antiviral Drugs Advisory Committee on immunosuppressive drugs

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 14, 1998, 8:30 a.m. to 5 p.m.

Location: Quality Suites, Potomac Ballroom, Three Research Ct., Rockville, MD.

Contact Person: Rhonda W. Stover or John B. Schupp, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 14, 1998, the subcommittee will discuss new drug application (NDA) 50–722, CellCept® (mycophenolate mofetil), Syntex, USA, Inc., for immunosuppression following cardiac transplantation.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 7, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person by January 7, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


William K. Hubbard, Associate Commissioner for Policy Coordination.

[FR Doc. 97–30561 Filed 11–20–97; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Antiviral Drugs Advisory Committee; Notice of Subcommittee Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.